Cargando…

Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine

This study investigated the immune response and outcome of BNT162b2 vaccination among 12 staff at a hospital in Fukushima, Japan. Blood samples were collected from participants before their first vaccination, with subsequent sampling performed during the participants’ work days for six weeks thereaf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobashi, Yurie, Shimazu, Yuzo, Kawamura, Takeshi, Nishikawa, Yoshitaka, Omata, Fumiya, Kaneko, Yudai, Kodama, Tatsuhiko, Tsubokura, Masaharu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Fukushima Society of Medical Science 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071351/ https://www.ncbi.nlm.nih.gov/pubmed/35228456 http://dx.doi.org/10.5387/fms.2021-28

Ejemplares similares

Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine
por: Kobashi, Yurie, et al.
Publicado: (2022)

A racing heart post‐Pfizer/BioNTech BNT162b2
por: Teo, Hooi Khee, et al.
Publicado: (2022)

Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
por: Hamada, Yohhei
Publicado: (2021)

Potential Triggers for Thrombocytopenia and/or Hemorrhage by the BNT162b2 Vaccine, Pfizer-BioNTech
por: Okada, Yusuke, et al.
Publicado: (2021)

Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
por: Li, Chunfeng, et al.
Publicado: (2022)

Syncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome
por: Altermanini, Mohammad, et al.
Publicado: (2023)

Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
por: Matsubara, Akihiro, et al.
Publicado: (2021)

Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey
por: Kobashi, Yurie, et al.
Publicado: (2022)

Cerebral Venous Sinus Thrombosis After Pfizer-BioNTech COVID-19 (BNT162b2) Vaccination
por: Cheng, Newman
Publicado: (2021)

Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
por: Sumi, Toshiyuki, et al.
Publicado: (2021)

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
por: Akiyama, Hiroaki, et al.
Publicado: (2021)

Vulvar Aphthous Ulcer in an Adolescent After Pfizer-BioNTech (BNT162b2) COVID-19 Vaccination
por: Wojcicki, Anna V., et al.
Publicado: (2022)

Efficacy of Vaccine BNT162b2 (Pfizer-BioNTech) in Individuals with Waldenstrom's Macroglobulinemia and Follicular Lymphoma in Australia
por: Beaton, Brendan, et al.
Publicado: (2021)

Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) Side Effects: A Systematic Review
por: Dighriri, Ibrahim M, et al.
Publicado: (2022)

Development of Flat Warts on the Cheeks after BioNTech-Pfizer BNT162b2 Vaccine: Is There a Correlation?
por: Cazzato, Gerardo, et al.
Publicado: (2022)

Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
por: Shimazawa, Rumiko, et al.
Publicado: (2021)

Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers
por: Alqassieh, Rami, et al.
Publicado: (2021)

The difference between IgM and IgG antibody prevalence in different serological assays for COVID-19; lessons from the examination of healthcare workers
por: Kobashi, Yurie, et al.
Publicado: (2021)

Waning of Humoral Immunity and the Influencing Factors after BNT162b2 Vaccination: A Cohort Study with a Latent Growth Curve Model in Fukushima
por: Kobashi, Yurie, et al.
Publicado: (2022)

High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers
por: Palich, R., et al.
Publicado: (2021)

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2021)

Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizer–BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2022)

Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community
por: Abukhalil, Abdallah Damin, et al.
Publicado: (2023)

Effectiveness of the BNT162b2 (Pfizer-BioNTech) Vaccine in Children and Adolescents: A Systematic Review and Meta-Analysis
por: Sabu, Jewel Maria, et al.
Publicado: (2022)

Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine
por: Islam, Nazmul, et al.
Publicado: (2022)

Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination
por: Algaissi, Abdullah, et al.
Publicado: (2022)

Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review
por: Cortés-Sarabia, Karen, et al.
Publicado: (2022)

Friend or foe—The Pfizer‐BioNTech (BNT162b2) vaccination: A case report of reversible acute acalculous cholecystitis
por: Wahlen, Bianca Maria, et al.
Publicado: (2022)

Cerebellar and brainstem stroke possibly associated with booster dose of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine
por: Thomas, Michael George, et al.
Publicado: (2023)

Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central Fukushima, Japan: A historical cohort study
por: Kobashi, Yurie, et al.
Publicado: (2021)

443. Pre-vaccination Antibody Titers Against Seasonal Coronaviruses And Antibody Responses to the Pfizer-BioNTech BNT162b2 COVID-19 mRNA Vaccine in Healthcare Workers
por: Laing, Eric, et al.
Publicado: (2021)

Stability testing of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine: a translational study in UK vaccination centres
por: Kudsiova, Laila, et al.
Publicado: (2021)

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)
por: Korth, Johannes, et al.
Publicado: (2021)

Recurrent erythema nodosum after the second dose of the Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
por: Wu, Xiaotian, et al.
Publicado: (2021)

Clinicopathological Characteristics of Inflammatory Myositis Induced by COVID-19 Vaccine (Pfizer-BioNTech BNT162b2): A Case Report
por: Kim, Ji Hyoun, et al.
Publicado: (2022)

Unusual Case of Painful Glossitis and Xerostomia Following Vaccination with Pfizer-BioNTech SARS-CoV-2 (BNT162b2)
por: Tan, Elina, et al.
Publicado: (2022)

Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions
por: Haq, Hannah N., et al.
Publicado: (2022)

Acute adrenal insufficiency in a patient with panhypopituitarism after vaccination against COVID-19 (BNT162b2 Pfizer-BioNTech)
por: González López, Javier, et al.
Publicado: (2022)

Intracranial Hemorrhage After Pfizer-BioNTech (BNT162b2) mRNA COVID-19 Vaccination: A Case Report
por: Yangi, Kivanc, et al.
Publicado: (2023)

Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
por: Walton, Muireann, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_utfb2aoeb0trt1mq6qu36j6rpb